Abstract
Three major cytokines, namely, tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous proinflammatory and pro-coagulant effects on endothelium. TNF-α expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Willebrand factor, platelet-activating factor and endothelin, suppression of the thrombomodulin-protein C-protein S system, reduction of tissue-plasminogen activator and release of plasminogen activator inhibitor-1. Research into the actions of IL-1β in the brain initially focused on its role in host defence responses to systemic disease. IL-1β can also elicit an array of responses which could either inhibit, exacerbate or induce neuronal damage and death. IL-6 can be induced by a variety of molecules including IL-1, TNF-α, transforming growth factor-β and prostaglandins (PGs), and many other mediators such as b-amyloid, interferon-g (IFNg) and IL-4 can potentiate these primary inducers, highlighting the complex nature of IL-6 modulation. Several studies reported that plasma levels of TNF-α and IL-6 are associated with prognosis after ischemic stroke and our group showed that plasma levels of cytokines such as TNF-α, IL-1β are different in every diagnostic subtype of ischemic stroke, and how plasma levels of some immunoinflammatory markers and thrombotic-phybrinolitic markers are predictive of acute ischemic stroke diagnosis in the acute setting.
Keywords: Ischemic Stroke, cytokines, tumor necrosis factor (TNF-α), Neurones, astrocytes, oligodendrocytes, Central Nervous System (CNS)
Current Pharmaceutical Design
Title: Inflammatory Cytokines in Acute Ischemic Stroke
Volume: 14 Issue: 33
Author(s): Antonino Tuttolomondo, Domenico Di Raimondo, Riccardo di Sciacca, Antonio Pinto and Giuseppe Licata
Affiliation:
Keywords: Ischemic Stroke, cytokines, tumor necrosis factor (TNF-α), Neurones, astrocytes, oligodendrocytes, Central Nervous System (CNS)
Abstract: Three major cytokines, namely, tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous proinflammatory and pro-coagulant effects on endothelium. TNF-α expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Willebrand factor, platelet-activating factor and endothelin, suppression of the thrombomodulin-protein C-protein S system, reduction of tissue-plasminogen activator and release of plasminogen activator inhibitor-1. Research into the actions of IL-1β in the brain initially focused on its role in host defence responses to systemic disease. IL-1β can also elicit an array of responses which could either inhibit, exacerbate or induce neuronal damage and death. IL-6 can be induced by a variety of molecules including IL-1, TNF-α, transforming growth factor-β and prostaglandins (PGs), and many other mediators such as b-amyloid, interferon-g (IFNg) and IL-4 can potentiate these primary inducers, highlighting the complex nature of IL-6 modulation. Several studies reported that plasma levels of TNF-α and IL-6 are associated with prognosis after ischemic stroke and our group showed that plasma levels of cytokines such as TNF-α, IL-1β are different in every diagnostic subtype of ischemic stroke, and how plasma levels of some immunoinflammatory markers and thrombotic-phybrinolitic markers are predictive of acute ischemic stroke diagnosis in the acute setting.
Export Options
About this article
Cite this article as:
Tuttolomondo Antonino, Di Raimondo Domenico, di Sciacca Riccardo, Pinto Antonio and Licata Giuseppe, Inflammatory Cytokines in Acute Ischemic Stroke, Current Pharmaceutical Design 2008; 14 (33) . https://dx.doi.org/10.2174/138161208786848739
DOI https://dx.doi.org/10.2174/138161208786848739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research Preface
Current Drug Targets - Infectious Disorders West Nile Virus Vaccine.
Current Drug Targets - Infectious Disorders Prevalence of Asymptomatic Cryptococcal Antigenemia and Association with Follow-up Risk of Cryptococcal Meningitis and Mortality among HIV Infected Patients in North West India: A Prospective Cohort Study
Current HIV Research Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Acanthamoeba-Bacteria: A Model to Study Host Interaction with Human Pathogens
Current Drug Targets Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Approaches for Drug Delivery to Central Nervous System
Current Drug Delivery Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology Penicillium marneffei and its Pulmonary Involvements
Current Respiratory Medicine Reviews Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued)